Drugs that contain Dabrafenib Mesylate

1. Drug name - TAFINLAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(7 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(7 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(8 years from now)

CN102083312A NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

CN102083312B NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

CN102655753A NOVARTIS Combination
Oct, 2030

(8 years from now)

CN102655753B NOVARTIS Combined Medicine
Oct, 2030

(8 years from now)

IN275655B NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

IN201004199P2 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636A4 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636B1 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636A2 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2488033A1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033B1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033A4 NOVARTIS Combination
Oct, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof Jun, 2025

(2 years from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds May, 2029

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct, 2030

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test; Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 75MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.